OverviewSuggest Edit
Daiichi Sankyo is a developer of pharmaceutical products. It engages in 4 businesses: the Innovative Pharmaceutical Business, the Generic Business, the Vaccine business, and the OTC-related business. The Innovative Pharmaceutical Business delivers a range of pharmaceuticals to patients ranging from the anticoagulant LIXIANA and other products in the primary care area to oncology products, among others, in the specialty care area. The Generic Business offers authorized generics (AG), or a new standard for generics featuring formulation, labelling, and packaging innovations that are easy to swallow but hard to swallow accidentally. The Vaccine business specializes in vaccines to prevent infectious diseases and develops a 3-valent combination vaccine containing three live attenuated viruses of measles, mumps, and rubella (MMR vaccine). The OTC-related business offers OTC drugs and a range of products including skincare cosmetics and oral care products.
| Type | Public | |
| Founded | 2005 | |
| HQ | Chuo City, JP | Map |
| Website | daiichisankyo.com |
Recent NewsAll News
- $81 Billion Worldwide Musculoskeletal Disorders Drugs Industry to 2030 - Featuring Pfizer, Abbott Laboratories and Daiichi Sankyo Among Others
- Global Influenza Vaccines Market Report 2021-2027 Featuring Emerging Players - Moderna, Novavax, Daiichi Sankyo, & Versatope Therapeutics
- Esperion Expands Partnership with Daiichi Sankyo Group to Additional Territories
- Global Acute Myeloid Leukemia (AML) Disease Market Report 2021 Featuring Apollomics, Astellas, BerGenBio, Chimerix, Daiichi Sankyo, Forma, GlycoMimetics, Kiadis, MacroGenics, Medigene & Piramal
Key People/Management at Daiichi Sankyo
Sunao Manabe
Toshiaki Sai
Satoru Kimura
Masahiko Ohtsuki
Shoji Hirashima
Noritaka Uji
Daiichi Sankyo Office Locations
Daiichi Sankyo Financials and Metrics
Daiichi Sankyo Revenue
| JPY | |
|---|---|
Revenue (Q2, 2020) | 243.2b |
Gross profit (Q2, 2020) | 156.8b |
Gross profit margin (Q2, 2020), % | 64.5% |
Net income (Q2, 2020) | 19.8b |
EBIT (Q2, 2020) | 24.3b |
Market capitalization (11-Jun-2021) | 4.9t |
Closing stock price (11-Jun-2021) | 2.6k |
Cash (30-Sept-2020) | 451.3b |
EV | 4.7t |
| JPY | Q1, 2018 | Q2, 2018 | Q3, 2018 | Q1, 2019 | Q2, 2019 | Q3, 2019 | Q1, 2020 | Q2, 2020 |
|---|---|---|---|---|---|---|---|---|
Depreciation and Amortization | 11.2b | 22.6b | 34.3b | 12.9b | 26.4b | 160.0b | 14.1b | 28.5b |
Inventories | (11.1b) | (12.1b) | (5.0b) | (12.5b) | (11.7b) | (4.9b) | (10.4b) | (10.2b) |
Accounts Payable | (27.4b) | 3.8b | 8.2b | (23.9b) | (59.0b) | (85.5b) | (30.3b) | (22.0b) |
Cash From Operating Activities | (11.8b) | 6.6b | 20.7b | 77.6b | 102.3b | 140.8b | 55.9b | (14.2b) |
| JPY | FY, 2018 |
|---|---|
EV/EBIT | -0.7 x |
EV/CFO | -0.5 x |
EV/FCF | -0.6 x |
Debt/Equity | 0.2 x |
Debt/Assets | 0.1 x |
Financial Leverage | 1.7 x |
P/E Ratio | 0.4 |
Daiichi Sankyo Acquisitions / Subsidiaries
| Company Name | Date | Deal Size |
|---|---|---|
| Im Co | October 08, 2015 | |
| Rice Force | October 08, 2015 | |
| Ambit Biosciences | September 29, 2014 | $410 m |
| Plexxikon Inc. | April 04, 2011 | $935 m |
| Ranbaxy Laboratories | November 30, 2008 | $4.6 b |
| U3 Pharma AG | May 26, 2008 | |
| Ambit Biosciences Corp. | ||
| American Regent, Inc. | ||
| Daiichi Sankyo | ||
| Daiichi Sankyo Biotech Co., Ltd. |
Daiichi Sankyo Revenue Breakdown
Daiichi Sankyo revenue breakdown by business segment: 92.8% from Prescription Drugs, 7.0% from Healthcare (OTC) Products and 0.2% from Other
Daiichi Sankyo revenue breakdown by geographic segment: 18.6% from North America, 9.8% from Europe, 61.9% from Japan and 9.7% from Other
Daiichi Sankyo Cybersecurity Score
Daiichi Sankyo Environment, Social & Governance (ESG) Ratings
Daiichi Sankyo Online and Social Media Presence
571 Twitter followers
Daiichi Sankyo has 571 Twitter Followers. The number of followers has increased 1.5% month over month and increased 4.7% quarter over quarter
Daiichi Sankyo's Trends
Daiichi Sankyo News and Updates
$81 Billion Worldwide Musculoskeletal Disorders Drugs Industry to 2030 - Featuring Pfizer, Abbott Laboratories and Daiichi Sankyo Among Others
Global Influenza Vaccines Market Report 2021-2027 Featuring Emerging Players - Moderna, Novavax, Daiichi Sankyo, & Versatope Therapeutics
Esperion Expands Partnership with Daiichi Sankyo Group to Additional Territories
Global Acute Myeloid Leukemia (AML) Disease Market Report 2021 Featuring Apollomics, Astellas, BerGenBio, Chimerix, Daiichi Sankyo, Forma, GlycoMimetics, Kiadis, MacroGenics, Medigene & Piramal
ViGeneron announces research collaboration with Daiichi Sankyo to evaluate vgAAV for novel ophthalmic gene therapy
Daiichi Sankyo Submits Supplemental Application in Japan for Approval of Partial Changes Related to Additional Indication for the Antiplatelet Agent, Prasugrel Hydrochloride
Daiichi Sankyo Frequently Asked Questions
When was Daiichi Sankyo founded?
Daiichi Sankyo was founded in 2005.
Who are Daiichi Sankyo key executives?
Daiichi Sankyo's key executives are Sunao Manabe, Toshiaki Sai and Satoru Kimura.
What is Daiichi Sankyo revenue?
Latest Daiichi Sankyo annual revenue is ¥981.8 b.
Who are Daiichi Sankyo competitors?
Competitors of Daiichi Sankyo include Bristol-Myers Squibb, Bayer and Boehringer Ingelheim.
Where is Daiichi Sankyo headquarters?
Daiichi Sankyo headquarters is located at 3-chōme-5-1 Nihonbashihonchō, Chuo City.
Where are Daiichi Sankyo offices?
Daiichi Sankyo has offices in Chuo City, Chiba, Chiyoda, Chiyoda City and in 38 other locations.
How many offices does Daiichi Sankyo have?
Daiichi Sankyo has 49 offices.
Learn about Craft real-time company insights
Receive alerts for 300+ data fields across thousands of companies